SUCCESSFUL MANAGEMENT OF DYSLIPIDEMIA THROUGH VAMANA KARMA: A CASE REPORT

Authors

  • Dr. Mehulkumar Subhash Patil
  • Dr. Payal D. Desai
  • Dr. Vishwa Dumasiya

DOI:

https://doi.org/10.5281/zenodo.21453136

Keywords:

Dyslipidemia, Medoroga, Dhatwagnimandhya, Ama, shodhana, Vaman Karma

Abstract

Dyslipidemia is a disorder in which the blood lipid levels become abnormal, i.e., either increase or decrease. Dyslipidemia is a recognized, independent, and modifiable risk factor for CAD and stroke. Even though effective therapy exists, the management of dyslipidemia still lacks optimal quality, and there is variability within different risk categories, populations, and gender. As per the Global Burden of Disease Study, the mortality rate for CAD is increasing in India. The prevalence of dyslipidemia in the Indian population was reported to be around 79%. Dyslipidemia can be linked with the condition Medoroga in Ayurveda, which refers to metabolic disorders associated with the abnormal deposition and incorrect distribution of Meda Dhatu in the body. It is a disease of Kapha dosha, Rasa dhatu, and Meda dhatu due to the presence of Ama produced by Dhatwagnimandhya. Since Medoroga is primarily a Santarpanottha Vyadhi, Shodhana Chikitsa, particularly Vamana Karma, is regarded as the treatment of choice for eliminating aggravated Kapha and correcting the underlying metabolic imbalance. Therefore, the present case study was undertaken to evaluate the therapeutic effect of Vamana Karma in the management of dyslipidemia. Through this case, the aim was to demonstrate that Vamana Karma, as a classical Ayurvedic Shodhana therapy, can effectively improve lipid profile parameters and serve as a beneficial treatment modality in the management of dyslipidemia.

Downloads

Download data is not yet available.

References

Rader DJ, Hoeg JM, Brewer HB. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 1994;120(12):1012-25.

Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022;43(4):611-53.

Blasco M, Ascaso JF; Grupo de Dislipidemia Aterogénica de la Sociedad Española de Arteriosclerosis. Control of the overall lipid profile. Clin Investig Arterioscler. 2019;31(Suppl 2):34-41.

Joshi SR, Anjana RM, Deepa M, Pradeepa R, Bhansali A, Dhandania VK, et al. Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study. PLoS One. 2014;9(5):e96808.

Huffman MD, Prabhakaran D, Osmond C, Fall CHD, Tandon N, Lakshmy R, et al. Incidence of cardiovascular risk factors in an Indian urban cohort: results from the New Delhi Birth Cohort. J Am Coll Cardiol. 2011;57(17):1765-74.

Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289-97.

Donkor ES. Stroke in the 21st century: a snapshot of the burden, epidemiology, and quality of life. Stroke Res Treat. 2018; 3238165.

Agnivesha. Charaka Samhita. Vimanasthana. Chapter 5, Verses 15-16. In: Shastri K, Chaturvedi G, editors. Varanasi: Chaukhambha Bharati Academy; p. 713.

Varma AA, Varma AJ. An observational clinical study on lipid profile changes before and after Shodhanarth Snehapan. Int Ayurvedic Med J. 2021.

Sastri PT, editor. Charaka Samhita of Agnivesha with Vidyotini Hindi Commentary. Rev ed. Sutra Sthana. Chapter 23, Verse 8. Varanasi: Chaukhamba Bharati Academy; 2008. p. 437.

Singh S, Srivastava AK. A clinical study to evaluate the efficacy of Vamana karma in the management of dyslipidemia. Asian J Pharm Clin Res. 2018;11(12).

Hridya A. Analysis of dyslipidemia as per Ayurveda and its management. Int J Ayurveda Pharma Res. 2022;10(10):68.

Downloads

Published

2026-07-20

Issue

Section

Original Research Article